Abstract Details

Title Feasibility of Using Blood-based Biomarkers to Evaluate the Effectiveness of Individualized Neurodegenerative Disease Preventive Care

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P4 - Poster Session 4 (11:45 AM-12:45 PM)

Poster/Presentation
Number 9-002

Background ND have an extended preclinical period. Early identification and intervention prior to dementia may offer the best opportunity to prevent or delay cognitive decline. Research suggests that blood-based biomarkers may be a reliable predictor of disease progression. The opportunity to use blood-based biomarkers to identify risk, monitor progression, and potentially guide individualized care represents a significant opportunity.

Objective Establish biorepository of blood-based biomarkers for neurodegenerative diseases (ND); assess feasibility of biomarker collection/processing in subjects at risk for dementia; incorporate concurrent phenotypic clinical data; and explore utility of blood-based biomarkers as outcome measures for n-of-1 trials.

Design/Methods Subjects with family history of ND with no or minimal cognitive and/or neurological complaints were recruited. Demographics, medical history, cognitive assessments and blood-based biomarkers for ND (via venipuncture and/or at-home finger prick card testing) were collected at baseline and longitudinally. Blood-based biomarkers included: Amyloid beta 42/40 ratio, pTau181, pTau231, pTau217, Neurofilament light and glial fibrillary acidic protein. Subjects may also opt-in to share relevant data from preventive clinical care.

Results 53 subjects (66% male, mean age 57.2, range 22-93, 62% ApoE4+) were enrolled. 75% of eligible subjects returned for follow-up assessments. A majority of subjects provided clinical data with biomarkers measured before and after risk reduction interventions prescribed by their physicians. Individualized clinical management consisted of various pharmacological therapies to address modifiable risk factors (e.g., tirzepatide, rosuvastatin, escitalopram), anti-amyloid therapies (e.g., aducanumab, lecanemab), other agents (e.g., rapamycin) and multi-modal lifestyle interventions (e.g., exercise, diet).

Conclusions In subjects at risk for dementia, it was feasible to collect/process blood-biomarkers. Several subjects had measurable changes in biomarkers of ND pathology and/or improvements or stabilization of cognition. Further research using blood-based biomarkers to evaluate the effectiveness of individualized ND preventive care in real-world clinical settings is needed.

Authors/Disclosures
Philip E. Sisser PRESENTER	Mr. Sisser has received personal compensation for serving as an employee of PAREF.
Kellyann Niotis, MD	Dr. Niotis has nothing to disclose.
Alon Seifan, MD (Cognitive Neurology Consultants, Inc. dba the Neuro Well)	Dr. Seifan has received personal compensation in the range of $100,000-$499,999 for serving as a Chief Science Officer with HB Biotech.
Shannon Helfman	No disclosure on file
Praveen Parthasarathy	No disclosure on file
Hollie Hristov, NP (Atria Institute)	Mrs. Hristov has nothing to disclose.
Juan Melendez-Herencia	No disclosure on file
Helena Colvee (IND Florida)	No disclosure on file
Jessica Lakis (IND Florida)	No disclosure on file
Christopher Janney (The Institute for Neurodegenerative Diseases (IND) Florida)	No disclosure on file
Kiarra Akiyoshi	No disclosure on file
Hanna Huber (University Gothenburg, Neurochemistry)	No disclosure on file
Nicholas Ashton (University of Gothenburg)	No disclosure on file
Henrik Zetterberg (Sahlgrenska University Hospital/Molndal)	No disclosure on file
Richard S. Isaacson, MD, FAAN	Dr. Isaacson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia. Dr. Isaacson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. The institution of Dr. Isaacson has received research support from National Institutes of Health. The institution of Dr. Isaacson has received research support from Aces for Alzheimer's. The institution of Dr. Isaacson has received research support from BrainMind. Dr. Isaacson has received publishing royalties from a publication relating to health care.